AJHE2316 - CME/CMLE - Application of the International Consensus Classification and World Health Organization 5th edition classification to a series of myeloid neoplasms-Application of the International Consensus Classification and World Health Organization 5th edition classification to a series of myeloid neoplasms

Application of the International Consensus Classification and World Health Organization 5th edition classification to a series of myeloid neoplasms

Back to course

Pdf Summary

The study compared the International Consensus Classification (ICC) and the 5th edition of the World Health Organization classification (WHO5) in terms of diagnosing myeloid neoplasms. A total of 237 cases were analyzed, with 56.5% classified as concordant, 26.6% having terminological differences, 15.6% showing minor diagnostic discrepancies, and 1.3% displaying major diagnostic discrepancies. Minor discrepancies included cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Major discrepancies involved cases initially diagnosed differently under the two systems, impacting therapeutic decisions. Notably, the study highlighted cases where terminological differences could affect clinical trial eligibility and therapy. The systems differed in blast count thresholds for certain diagnoses, raising concerns about potential variations in treatment approaches. Most cases aligned between the two classifications, but discrepancies, even if seemingly minor, could have practical implications for patient care and treatment decisions. The study emphasized the need for harmonization of these classification systems to prevent confusion and ensure consistency in diagnosing myeloid neoplasms, ultimately aiming to streamline patient management and improve clinical outcomes.

Keywords

International Consensus Classification

ICC

5th edition

World Health Organization classification

WHO5

myeloid neoplasms

diagnostic discrepancies

myelodysplastic syndrome

acute myeloid leukemia

therapeutic decisions